The study by Kocatürk et al. evaluates the effectiveness of autologous whole blood (AWB) and autologous serum (AS) injections compared to placebo in patients with chronic spontaneous urticaria (CSU) who have a positive autologous serum skin test (ASST). Chronic spontaneous urticaria is a condition characterized by spontaneous appearance of hives or angioedema lasting for more than six weeks, often associated with autoreactive antibodies. The ASST is a diagnostic tool used to identify patients who might benefit from therapies targeting these autoreactive processes.

A total of 88 patients were enrolled in this placebo-controlled, randomized, single-blind study. They were divided into ASST-positive (ASST+) and ASST-negative (ASST-) groups and randomized to receive weekly injections of either AWB, AS, or placebo for 10 weeks. The primary outcomes measured were changes in the urticaria activity score (UAS) and the dermatology life quality index (DLQI).

Results indicated that in ASST+ patients, both AWB and AS injections led to improvements in UAS and DLQI scores, but these improvements were not significantly different from those observed in the placebo group. Specifically, 85% of ASST+ patients in the AWB group, 65% in the AS group, and 79% in the placebo group showed more than 30% improvement in UAS scores. Similarly, 90% of ASST+ patients in both the AWB and placebo groups showed more than 30% improvement in DLQI scores, compared to 65% in the AS group. In ASST- patients, the improvements were also similar across the three groups, with no significant intergroup differences.

The study concludes that while AWB and AS injections appear to provide some clinical benefits in reducing urticaria activity and improving quality of life, these effects are comparable to those of placebo. The findings suggest that the therapeutic efficacy of AWB and AS injections may be influenced by psychological or placebo effects, rather than specific immunomodulatory actions. Therefore, while these treatments are not recommended as primary therapeutic strategies for CSU, they may still offer some symptomatic relief in certain patients.

The immunomodulatory properties of autologous blood therapies align with the objectives of Novastem's stem cell therapies, which aim to treat autoimmune and inflammatory conditions by modulating immune responses and reducing inflammation. Similar to the effects observed with AWB and AS injections, stem cell therapies may offer potential benefits in managing chronic spontaneous urticaria and other related conditions by enhancing immune regulation and promoting tissue repair.

• Mechanism of Action: AWB and AS therapies are believed to modulate immune responses by inducing tolerance to circulating histamine-releasing factors and autoreactive antibodies, which are crucial for managing CSU.
• Clinical Benefits: The study demonstrated that both AWB and AS injections could reduce urticaria activity and improve quality of life in patients with CSU, although these effects were not significantly different from placebo.
• Potential for Broad Application: The findings suggest that while AWB and AS therapies may not be superior to placebo, their immunomodulatory effects could complement other treatment modalities, highlighting the potential for integrating these therapies in broader clinical practice.

#AutologousWholeBlood #AutologousSerum #ChronicSpontaneousUrticaria #ImmuneModulation #PlaceboControlledStudy #QualityOfLife #StemCellTherapy